Carlo Conti

Of Counsel

Practice Areas:

Life Sciences and Health Law
Constitutional and Administrative Law
Corporate and Commercial

Functions:

Numerous mandates as President or Member of the Board of Directors of various companies
President or Board Member of various organisations

Career:

2023	Of counsel Wenger Plattner
2016	Partner Wenger Plattner
2014	Of counsel Wenger Plattner
2000	Member and Vice-President of the Cantonal Government Basel-Stadt, Head of the Department of Public Health
1985	F. Hoffmann-La Roche AG, in senior management position Legal Department and Public Relations
1985	University of Basel (Dr. iur.)
1982	Attorney at Law
1978	University of Basel (lic. iur.)

 

Selected publications:

Digital Health Laws and Regulations Switzerland 2024
In: The International Comparative Legal Guides (ICLG), Fifth Edition, London 2024, p. 205-213

Drug & Medical Device Litigation 2023 - Practical cross-border insights into drug and medical device litigation
In: The International Comparative Legal Guides (ICLG), Fourth Edition, London 2023, p. 135-142

GLI - Pricing & Reimbursement 2022
GLI - Pricing & Reimbursement 2022, Fifth Edition, p. 218 - 227

Kommentar zu Art. 16a - 16c HMG
In: Eichenberger/Jaisli/Richli (Hrsg.), Basler Kommentar zum Heilmittelgesetz, 2. Aufl., Basel, 2022

GLI - Pricing & Reimbursement 2021
GLI – Pricing & Reimbursement 2021, Fourth Edition, p. 195 - 204

GLI - Pricing & Reimbursement 2020
Every resident in Switzerland is mandatorily obliged to be covered by basic healthcare insurance which provides for a wide range of services. Persons with lower incomes are, in principle, granted reductions on the premiums payable for such basic healthcare insurance. Thus, every resident in Switzerland is granted access to affordable healthcare. In general, therapeutic products are only reimbursed if they are listed on the so-called specialty list. In order to be listed thereon, a medicinal product must be admitted by the competent Swiss authority, and must satisfy the criteria of effectiveness, functionality and economic efficiency, based on which the maximum price for the therapeutic product in question is determined.

The Pharma Legal Handbook Switzerland
Regulatory, Pricing and Reimbursement Overview · Preclinical and Clinical Trial Requirements · Marketing, Manufacturing, Packaging and Labeling Advertising · Traditional Medicines and OTC Products · Product Liability · Patents and Trademarks · Regulatory Reforms | Pharma Board Room, London 2020

GLI - Pricing & Reimbursement 2019
Every resident in Switzerland is mandatorily obliged to be covered by basic healthcare insurance which provides for a wide range of services. Persons with lower incomes are, in principle, granted reductions on the premiums payable for such basic healthcare insurance. Thus, every resident in Switzerland is granted access to affordable healthcare. In general, therapeutic products are only reimbursed if they are listed on the so-called specialty list. In order to be listed thereon, a medicinal product must be admitted by the competent Swiss authority, and has to satisfy the criteria of effectiveness, functionality and economic efficiency, based on which the maximum price for the therapeutic product in question is determined.

GLI – Pricing & Reimbursement 2018
Every resident in Switzerland is mandatorily obliged to be covered by basic healthcare insurance which provides for a wide range of services. Persons with lower incomes are in principle granted reductions on the premiums payable for such basic healthcare insurance. Thus, every resident in Switzerland is granted access to affordable healthcare.

Versorgungsmanagement im Spannungsfeld zwischen Daten-, Patientenschutz und sektoralen Versorgungsgrenzen (in German)
In: Versorgungsmanagement in Gesundheitssystemen, Rebscher Herbert / Kaufmann Stefan (Hrsg.), Heidelberg 2013, S. 139 ff.